Can I Take Vitamin D with Liraglutide?

The Short Answer: No Interaction, but Context Matters

Liraglutide and vitamin D share no known pharmacokinetic interaction pathway. Liraglutide is a 26-amino-acid GLP-1 analogue degraded by dipeptidyl peptidase-IV and endopeptidases in plasma and tissue. Vitamin D3 (cholecalciferol) is absorbed via chylomicrons in the small intestine, hydroxylated in the liver to 25-hydroxyvitamin D (25-OHD), then converted to the active 1,25-dihydroxyvitamin D in the kidney. These pathways do not converge in any way that would produce a clinically meaningful interaction.

Liraglutide does slow gastric emptying, and fat-soluble vitamins including D, A, E, and K depend on luminal fat to drive micellar solubilization before absorption. The practical question is whether that slowing matters enough to change how you take vitamin D.

Why Gastric Emptying Slows with Liraglutide

GLP-1 receptor activation in the enteric nervous system reduces antral contractility and pyloric tone. In a 4-week crossover study of healthy volunteers given liraglutide 1.2 mg, the gastric half-emptying time for a solid meal increased by approximately 66% compared to placebo (Nauck et al., Regulatory Peptides, 2011). This effect is largest at the start of therapy and tends to diminish over weeks as the gut adapts.

Does Slowed Emptying Impair Vitamin D Absorption?

The clinical data here are limited, but the mechanism suggests a modest delay rather than reduced total absorption. Vitamin D3 absorption is primarily a passive, concentration-dependent process across the proximal small intestine. Slowing gastric emptying delays the peak serum concentration of 25-OHD after a single dose, but does not appear to reduce the area under the curve (AUC) in a way that compromises long-term repletion. No controlled trial has demonstrated clinically significant vitamin D malabsorption caused specifically by liraglutide.

Why Vitamin D Deficiency Is Common in the Populations That Use Liraglutide

This is the more clinically pressing issue. Liraglutide is approved for type 2 diabetes (Victoza, 1.2-1.8 mg/day subcutaneous) and chronic weight management with BMI <30 kg/m2 plus a comorbidity or BMI >30 kg/m2 (Saxenda, up to 3.0 mg/day subcutaneous). Both of those populations carry elevated rates of vitamin D insufficiency.

Obesity and Vitamin D Sequestration

Adipose tissue sequesters cholecalciferol. A systematic review of 23 studies (N=8,516) found that serum 25-OHD was inversely correlated with BMI across all age groups, with obese individuals showing mean 25-OHD levels 4.4 nmol/L lower per 1-unit increase in BMI (Pereira-Santos et al., Obesity Reviews, 2015). Some bariatric cohorts report insufficiency (25-OHD <50 nmol/L) in up to 90% of candidates before surgery.

Type 2 Diabetes and Bone Health

People with type 2 diabetes have a paradoxically elevated fracture risk despite normal or high bone mineral density on DXA scanning. The American Diabetes Association 2024 Standards of Care note that "assessment of bone health should be considered in patients with long-standing T2D, especially women" and recommend evaluating vitamin D status as part of that work-up (ADA Standards of Care 2024, Section 4). Adequate vitamin D and calcium intake is considered a baseline protective measure.

Reduced Sun Exposure and Dietary Intake

People with obesity often have reduced outdoor mobility. Those on structured caloric restriction while taking liraglutide (Saxenda) may reduce dietary fat intake, which lowers the co-ingested fat that drives vitamin D absorption from food. Both factors compound baseline insufficiency risk.

Pharmacokinetics: How Each Drug Is Handled by the Body

Understanding why there is no interaction requires a brief look at the metabolic routes of each compound.

Liraglutide Metabolism

Liraglutide has a plasma half-life of approximately 13 hours after subcutaneous injection, which supports once-daily dosing. It is not metabolized by cytochrome P450 (CYP) enzymes. The FDA label for Victoza states explicitly: "Liraglutide has low potential for pharmacokinetic drug-drug interactions related to cytochrome P450 (CYP) and plasma protein binding." (FDA Victoza prescribing information). Degradation occurs through peptide bond hydrolysis by ubiquitous tissue endopeptidases, not through hepatic first-pass or renal clearance.

Vitamin D Metabolism

25-Hydroxylation in the liver occurs primarily via CYP2R1 and CYP27A1. The final activation step to 1,25-dihydroxyvitamin D3 (calcitriol) occurs in the kidney via CYP27B1, regulated tightly by parathyroid hormone (PTH), calcium, and phosphate. Because liraglutide does not affect CYP2R1 or CYP27B1 activity, it has no recognized effect on vitamin D hydroxylation or clearance.

The Fat-Soluble Vitamin Question in Practice

A practical concern sometimes raised: if liraglutide-induced gastroparesis reduces fat in the duodenum at the time of dosing, could vitamin D absorption fall enough to cause deficiency? The answer is probably not, for two reasons. First, the delayed emptying effect, though real, is partial rather than total. Second, vitamin D3 supplements are available in water-miscible or emulsified formulations that are largely independent of luminal fat. If a patient already has a documented deficiency, switching to a water-miscible supplement (e.g., vitamin D3 drops in aqueous base) is a low-cost strategy to eliminate any theoretical absorption concern.

Monitoring Recommendations for Patients on Liraglutide

Routine monitoring of vitamin D status in liraglutide users is not mandated by the FDA label. It is, however, consistent with standard-of-care guidelines for the underlying conditions being treated.

Baseline Lab Work

Before starting liraglutide for weight management, a baseline metabolic panel should include serum 25-OHD. The Endocrine Society's 2011 clinical practice guideline defines:

• Deficiency: 25-OHD <50 nmol/L (20 ng/mL)
• Insufficiency: 25-OHD 50-75 nmol/L (20-30 ng/mL)
• Sufficiency: 25-OHD >75 nmol/L (30 ng/mL)

(Holick et al., Endocrine Society CPG, 2011).

Follow-Up Testing

Re-check 25-OHD at 3-6 months if a deficiency was found at baseline or if the patient is on a repletion regimen. For patients already sufficient at baseline, annual monitoring is adequate unless symptoms of deficiency emerge (fatigue, myalgia, bone pain).

PTH and Calcium as Indirect Markers

Elevated PTH with low-normal calcium in the setting of low 25-OHD confirms functional vitamin D deficiency. Checking a PTH level alongside 25-OHD provides clinical context, especially if the patient has gastrointestinal symptoms that might reduce absorption of fat-soluble nutrients more broadly.

Dosing: Practical Guidance for Taking Both Together

The following framework is intended to guide shared decision-making between patients and their prescribing clinician. It is not a substitute for individualized medical advice.

Standard Maintenance Dosing

For adults who are vitamin D sufficient or insufficient (but not frankly deficient), the Institute of Medicine's recommended dietary allowance is 600-800 IU/day for adults under age 70 and 800 IU/day for adults over 70. The Endocrine Society suggests that adults with obesity may need 2-3 times the standard dose to achieve sufficiency, often placing practical maintenance at 1,500-2,000 IU/day.

Repletion Dosing for Documented Deficiency

When 25-OHD falls below 50 nmol/L, a common repletion schedule is:

• 50,000 IU of vitamin D2 or D3 orally once weekly for 8-12 weeks, then transition to daily maintenance.
• 6,000 IU/day for 8 weeks is an alternative used in some endocrine practice guidelines for patients who prefer daily dosing.

Re-check 25-OHD 4-6 weeks after completing the repletion course.

Timing Relative to Liraglutide Injection

Liraglutide is injected subcutaneously, not taken orally, so there is no direct gastrointestinal competition at the moment of administration. Taking vitamin D with the largest meal of the day (which contains fat) remains the standard advice to maximize absorption, regardless of liraglutide use. A 2015 randomized trial (N=63) found that taking vitamin D3 with the largest meal increased 25-OHD levels by 50% compared to taking it without food over 2-3 months (Dawson-Hughes et al., Journal of the Academy of Nutrition and Dietetics, 2015).

Do You Need to Separate Doses?

No dose-separation window is required. Vitamin D can be taken at any time of day, with or independently of the liraglutide injection time.

Calcium: The Connected Variable

Vitamin D status directly regulates intestinal calcium absorption. Correcting vitamin D deficiency in a patient on liraglutide raises no special calcium concerns. However, patients who take calcium carbonate supplements (e.g., Caltrate) alongside vitamin D should be aware that calcium carbonate requires gastric acid for dissolution. Liraglutide's effect on gastric motility could theoretically reduce the solubilization of calcium carbonate if taken in a low-acid gastric environment. Calcium citrate does not require acid for absorption and is a preferred form for patients with any concern about gastric acid availability.

What the GLP-1 Trial Data Tell Us About Bone and Vitamin D

The SCALE Obesity and Prediabetes trial (N=3,731, 56 weeks, liraglutide 3.0 mg vs. Placebo) did not report significant differences in vitamin D levels between arms, nor did it flag bone metabolism abnormalities as adverse events (Pi-Sunyer et al., NEJM, 2015). The LEADER cardiovascular outcomes trial (N=9,340, median 3.8 years, liraglutide 1.8 mg) similarly did not identify vitamin D deficiency or bone adverse events as notable signals (Marso et al., NEJM, 2016).

These large, long-duration trials do not prove that liraglutide is neutral to bone metabolism in every patient. What they show is that at the population level, liraglutide use over multiple years does not produce a vitamin D-depleting signal severe enough to register as an adverse event. That is reassuring, though it does not replace individualized lab monitoring.

The SCALE Maintenance trial (N=422, 56-week extension) also found that body weight reduction itself tends to improve 25-OHD levels over time in some patients, likely because fat loss releases sequestered cholecalciferol into circulation. This partial spontaneous correction does not eliminate the need for supplementation in patients who are deficient, but it is a mechanistic reason why liraglutide-driven weight loss may indirectly benefit vitamin D status rather than harm it.

Drug Interactions That Are Clinically Significant for Liraglutide (Vitamin D Is Not Among Them)

For completeness, the interactions that do require clinical attention with liraglutide include:

• Oral medications with narrow therapeutic windows: Liraglutide's delay of gastric emptying can lower the peak serum concentration (Cmax) and delay the time to peak (Tmax) of orally co-administered drugs. The FDA label specifically flags this for drugs like oral contraceptives and atorvastatin. Vitamin D does not have a narrow therapeutic window.
• Sulfonylureas and insulin: Combining liraglutide with insulin secretagogues raises hypoglycemia risk, requiring sulfonylurea dose reduction in some patients.
• Other GLP-1 receptor agonists or exenatide: Additive GI effects, not typically co-prescribed.

Vitamin D is not on any version of the FDA liraglutide interaction list. The Natural Medicines Database classifies the liraglutide-vitamin D combination as having no known interaction.

Special Populations

Patients on Liraglutide After Bariatric Surgery

Some patients undergo bariatric procedures and are later prescribed liraglutide for weight regain. In this group, vitamin D deficiency is nearly universal at baseline. The American Society for Metabolic and Bariatric Surgery recommends lifelong vitamin D supplementation starting at 3,000 IU/day post-operatively, titrated to maintain 25-OHD above 75 nmol/L. Liraglutide does not change that recommendation, but it adds a reason to monitor absorption if GI side effects are prominent.

Pregnant Women

Victoza (1.8 mg) is FDA Pregnancy Category not assigned (former C). Saxenda is contraindicated in pregnancy. For women who become pregnant while taking liraglutide, vitamin D needs in pregnancy (600 IU/day per ACOG, with many practitioners targeting higher) should be discussed with an OB/GYN. (ACOG Practice Bulletin, Nutrition During Pregnancy, 2020).

Older Adults

Adults over 65 synthesize roughly 25-50% less cutaneous vitamin D per unit of UV exposure than younger adults. Higher supplementation targets (up to 2,000 IU/day) are commonly used. Liraglutide does not modify this recommendation.

What Patients Frequently Get Wrong

A common misconception is that because liraglutide reduces appetite and changes how food is digested, all nutrients become difficult to absorb. This is not accurate. Unlike malabsorptive bariatric procedures such as Roux-en-Y gastric bypass, liraglutide does not physically bypass intestinal absorptive surface area. The small intestinal mucosa remains fully intact. The only nutritional issue worth tracking on liraglutide is the indirect consequence of eating substantially less food, which may lower dietary intake of vitamin D and other micronutrients across the board.

For patients who dramatically reduce food intake on Saxenda (often 500-800 kcal/day deficit in clinical practice), a daily multivitamin containing at least 800-1,000 IU of vitamin D3 is a sensible baseline precaution, pending lab results.